SecSonar.com

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Aquestive Therapeutics, Inc. (AQST) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $404.7M. Revenue declined 22.6% year-over-year and free cash flow was negative at -$53M. This page tracks AQST's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 142 employees · IPO Jul 25, 2018

Valuation

Valuation & price

$4.17 · as of May 17, 2026 · -44.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$7.04$5.10$3.16Jul 25Dec 25Jul 26Jul 7, 25$3.70Jul 9, 25$4.01Jul 11, 25$4.01Jul 15, 25$4.02Jul 17, 25$4.37Jul 21, 25$4.23Jul 23, 25$4.26Jul 25, 25$4.15Jul 29, 25$3.93Jul 31, 25$3.84Aug 4, 25$4.02Aug 6, 25$3.99Aug 11, 25$3.86Aug 13, 25$4.01Aug 15, 25$4.11Aug 19, 25$3.85Aug 21, 25$3.91Aug 25, 25$3.86Aug 27, 25$3.85Aug 29, 25$3.77Sep 3, 25$3.95Sep 5, 25$5.42Sep 9, 25$4.98Sep 11, 25$4.95Sep 16, 25$4.87Sep 18, 25$4.94Sep 22, 25$5.17Sep 24, 25$5.42Sep 26, 25$5.99Sep 30, 25$5.59Oct 2, 25$5.77Oct 6, 25$5.97Oct 8, 25$6.20Oct 10, 25$6.54Oct 14, 25$6.88Oct 16, 25$7.01Oct 21, 25$7.04Oct 23, 25$7.02Oct 27, 25$7.00Oct 29, 25$6.48Oct 31, 25$6.82Nov 4, 25$6.08Nov 6, 25$6.13Nov 10, 25$5.58Nov 12, 25$5.58Nov 14, 25$5.39Nov 18, 25$5.91Nov 20, 25$5.62Nov 25, 25$6.09Nov 28, 25$6.19Dec 2, 25$5.93Dec 4, 25$6.44Dec 8, 25$6.62Dec 10, 25$6.23Dec 12, 25$6.21Dec 16, 25$5.82Dec 18, 25$5.81Dec 22, 25$5.96Dec 24, 25$5.97Dec 29, 25$6.47Jan 2, 26$6.45Jan 6, 26$6.24Jan 8, 26$6.21Jan 12, 26$3.51Jan 14, 26$3.52Jan 16, 26$3.31Jan 21, 26$3.36Jan 23, 26$3.24Jan 27, 26$3.47Jan 29, 26$3.16Feb 2, 26$4.10Feb 4, 26$4.00Feb 9, 26$3.94Feb 11, 26$3.82Feb 13, 26$3.65Feb 18, 26$3.83Feb 20, 26$3.95Feb 24, 26$4.09Feb 26, 26$4.11Mar 2, 26$4.21Mar 4, 26$4.37Mar 6, 26$4.22Mar 10, 26$4.20Mar 12, 26$4.03Mar 17, 26$4.11Mar 19, 26$4.06Mar 23, 26$3.93Mar 25, 26$4.21Mar 27, 26$4.02Mar 31, 26$4.15Apr 2, 26$4.13Apr 7, 26$4.13Apr 9, 26$4.17Apr 13, 26$4.19Apr 15, 26$4.24Apr 17, 26$4.32Apr 22, 26$4.15Apr 24, 26$4.08Apr 28, 26$4.09Apr 30, 26$4.10May 4, 26$4.22May 6, 26$4.23May 8, 26$4.32May 12, 26$4.16May 14, 26$4.73May 18, 26$4.14May 20, 26$4.17May 22, 26$4.12May 28, 26$4.02Jun 1, 26$4.00Jun 3, 26$4.03Jun 5, 26$3.93Jun 9, 26$3.99Jun 11, 26$4.21Jun 15, 26$4.22Jun 17, 26$4.43Jun 22, 26$4.72Jun 24, 26$4.99Jun 26, 26$4.39Jul 2, 26$4.18
$2.9552-week range$7.49
Loading valuation history…

Fundamentals

Key fundamentals

$404.7M

Market cap

-22.6%

Revenue growth (YoY)

61.5%

Gross margin

-$53M

Free cash flow (USD)

$10.3M

Net debt

40.6%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$51.8MFY 2017$66.9MFY 2018$67.4MFY 2019$52.6MFY 2020$45.8MFY 2021$50.8MFY 2022$47.7MFY 2023$50.6MFY 2024$57.6MFY 2025$44.5M
$51.8M$44.5M

Free cash flow by year

2016 → 2025

FY 2016$-9.2MFY 2017$3.8MFY 2018$-14.8MFY 2019$-60.9MFY 2020$-46.0MFY 2021$-33.9MFY 2022$-12.3MFY 2023$-7.4MFY 2024$-35.9MFY 2025$-53.0M
-$9.2M-$53M

Gross margin by year

2021 → 2025

FY 202170.5%FY 202259.3%FY 202358.8%FY 202469.0%FY 202561.5%
70.5%61.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • FinancingSecurities RegistrationJun 26, 2026Filing
  • Insider sellInsider Sell $125K · 10b5-1 PlanKrop Julie · Director · $125.4KJun 24, 2026Filing
  • Insider sellInsider Sell $104KBarber Daniel · President and CEO · $104KJun 16, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • Insider sellInsider Sell $35KBarber Daniel · President and CEO · $35.4KMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing

Questions

Frequently asked questions

What is Aquestive Therapeutics, Inc.'s market cap?

Aquestive Therapeutics, Inc. (AQST) has a market capitalization of $404.7M.

What is AQST's P/E ratio?

A meaningful P/E ratio is not available for AQST — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying AQST stock?

SEC Form 4 filings show no open-market insider buys at Aquestive Therapeutics, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

SNDL

SNDL Inc.

$383.8M

EOLS

Evolus, Inc.

$434.3M

KMDA

Kamada Ltd.

$451.4M

CGC

Canopy Growth Corporation

$468.3M

SIGA

SIGA Technologies, Inc.

$340.3M

ORGO

Organogenesis Holdings Inc.

$331.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.